Plerixafor: In Patients with Non-Hodgkin's Lymphoma or Multiple Myeloma

Author： Wagstaff Antona J.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.69, Iss.3, 2009-02, pp. : 319-326

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma

By Hellmann Andrzej  

Clinical Pharmacokinetics, Vol. 50, Iss. 12, 2011-12 ,pp. : 781-791

Adis International

Access to resources Recommend Favorite

Bendamustine: A Review of its Use in the Management of Chronic Lymphocytic Leukaemia, Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma and Multiple Myeloma

By Hoy Sheridan M.  

Drugs, Vol. 72, Iss. 14, 2012-10 ,pp. : 1929-1950

Adis International

Access to resources Recommend Favorite

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma

By Quinn David I.  

Clinical Pharmacokinetics, Vol. 48, Iss. 3, 2009-01 ,pp. : 199-209

Adis International

Access to resources Recommend Favorite

Immunosuppressants: non-Hodgkin's lymphoma in patients with IBD

By  

Inpharma, Vol. 1, Iss. 1323, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Plerixafor: A Review of its Use in Stem-Cell Mobilization in Patients with Lymphoma or Multiple Myeloma

By Keating Gillian M.  

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1623-1647

Adis International

Access to resources Recommend Favorite